RELEVANCE AND PROSPECTS OF BIOLOGIC THERAPY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

Abstract

Our research group studied the presence and amount of tumour necrosis factor in the blood, before and after treatment with monoclonal antibodies. Sampling for analysis was carried out at INNOVA, a private medical research clinic in Samarkand, Uzbekistan. As part of our study patients were treated with biologics against systemic lupus erythematosus at the City Medical Association in Samarkand, in the Department of Cardio-Rheumatology, and at the 1^st clinic of Samarkand Medical Institute in the Therapy Department #1.

In the course of treatment, our research team observed clinical and laboratory improvement after application of monoclonal antibodies, unlike other drugs such as steroid hormones or cytostatics